title: Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
abstract: The objective of this study was to compare allogeneic bone marrow transplantation (BMT) with high-dose cytarabine containing chemotherapy in children with acute myeloid leukemia (AML) in first complete remission (CR). One hundred and seventy-one children were enrolled on the LAME89/91 protocol. Induction chemotherapy was a combination of cytarabine and mitoxantrone. After achieving CR, patients who had an HLA-identical sibling donor underwent allogeneic BMT. Children not eligible for BMT received post remission chemotherapy which included two consolidation courses, the second consolidation consisting of high-dose cytarabine with amsacrine and asparaginase. CR was achieved in 149 children (87%). Thirty-two had an HLA-identical sibling donor and were eligible for BMT. These 32 patients, as well as an additional child who had a one antigen HLA-mismatched father, received BMT during first CR. Consequently, 33 patients were analyzed in the BMT group and 116 in the chemotherapy group. The 4-year probability of relapse was 26 +/- 15% in the BMT group and 47 +/- 10% in the chemotherapy group (P = 0.04). The risk of therapy-related death was 3% for BMT and 7.7% for chemotherapy. Disease-free survival (DFS) was 72 +/- 15% in the BMT group and 48 +/- 10% in the chemotherapy group (p = 0.02). We conclude that allogeneic BMT from a matched sibling donor is the treatment of choice for reducing the relapse risk and for increasing DFS in children with AML in first CR.
authors.affiliation: Hôpital d'Enfants la Timone, Marseille, France.
authors.forename: G
authors.initials: G
authors.lastname: Michel
authors.forename: G
authors.initials: G
authors.lastname: Leverger
authors.forename: T
authors.initials: T
authors.lastname: Leblanc
authors.forename: B
authors.initials: B
authors.lastname: Nelken
authors.forename: A
authors.initials: A
authors.lastname: Baruchel
authors.forename: J
authors.initials: J
authors.lastname: Landman-Parker
authors.forename: I
authors.initials: I
authors.lastname: Thuret
authors.forename: C
authors.initials: C
authors.lastname: Bergeron
authors.forename: P
authors.initials: P
authors.lastname: Bordigoni
authors.forename: H
authors.initials: H
authors.lastname: Esperou-Bourdeau
authors.forename: Y
authors.initials: Y
authors.lastname: Perel
authors.forename: J P
authors.initials: JP
authors.lastname: Vannier
authors.forename: G
authors.initials: G
authors.lastname: Schaison
mesh_terms: D000677:Amsacrine / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D016026:Bone Marrow Transplantation / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality; D006648:Histocompatibility; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy*; D015993:Life Tables; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009679:Nuclear Family; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000677:Amsacrine; D003561:Cytarabine; D008942:Mitoxantrone; D001215:Asparaginase